Tongxinluo Capsule in Ischemic Stroke Patients（TISS)

NCT ID: NCT01919671

Last Updated: 2017-01-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 2007 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-31
• Study Completion Date: 2016-11-30

Brief Summary

The purpose of this study is to assess the effects in improving life self-care ability of stroke patients after taking Tongxinluo Capsule(within 72 hours after onset) versus Placebos for 90 days.

Detailed Description

The study is a randomized, double-blind, placebo controlled, multi-center trial. We aim to enroll a total of 1968 individuals(984 cases in each group) with acute ischemic stroke less than 72 hours after onset. Participants will be randomized into Tongxinluo capsule treatment group with the capsule administration of 4 granules tid. for 90 days, while the patients in the control group receive placebo capsule. NIH Stroke Score of the subjects is 4-22 at randomization. Evaluations of efficacy and safety will be taken at baseline, 7 days, discharge date and 90 days. Neuroimaging [magnetic resonance imaging (MRI) scans] will be obtained at baseline and 90 days after therapy. The primary efficacy endpoint is the proportion of Modified Rankin Scale (mRS) ≤1 at 90 days.

Conditions

Ischemic Stroke

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Tongxinluo capsule

Tongxinluo capsule,4 granules,t.i.d. po,for 90 days

Group Type: EXPERIMENTAL

Tongxinluo capsule

Intervention Type: DRUG

for 90 days

placebo capsule

placebo capsule,4 granules,t.i.d. po,for 90 days

Group Type: PLACEBO_COMPARATOR

placebo capsule

Intervention Type: DRUG

for 90 days

Interventions

Tongxinluo capsule

for 90 days

Intervention Type: DRUG

placebo capsule

for 90 days

Intervention Type: DRUG

Other Intervention Names

Yiling Pharmaceutical，Z19980015; placebo

Eligibility Criteria

Inclusion Criteria

• Ischemic stoke within 72 after onset, confirmed by MRI or CT.
• Age 35-75 years, inclusive.
• Patients with the first attack or patients with stroke history(modified Rankin Scale score 0-1).
• Clear signs of localization of nervous system, NIHSS score 4 to 22.
• Patient or proxy has signed informed consent.

Exclusion Criteria

• Hemorrhage diseases according to head CT or MRI, such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, haemorrhage after cerebral infarction.
• Transient Ischemic Attack (TIA).
• Severe disturbance of consciousness: 1a of NIHSS score>1 point; Difficulty in swallowing, unable to take oral capsules; any of 5a, 5b, 6a, 6b of NIHSS score>2 point.
• Convinced of stroke caused by brain tumor, brain trauma, hemopathy, etc.
• Hemorrhagic tendency patients.
• Patients with endovascular treatment after the onset of stroke.
• Patients with dementia, severe Parkinson's disease, mental disorders, limb dysfunction caused by other diseases or other conditions that may affect the therapeutic efficacy.
• Uncontrolled hypertension (≥200 mmHg systolic or ≥110 mmHg diastolic) or hypotension (≤90 mmHg systolic or ≤60mmHg diastolic); severe hyperglycemia(blood glucose ≥400 mg/dl) or hypoglycemia( blood glucose≤50 mg/dl).
• Severe hepatic insufficiency defined as transaminase values > 2x upper limit of normal; severe renal insufficiency defined as values serum creatinine> 1.5x upper limit of normal; cardiac dysfunction or other serious systemic disease with life expectancy ≤3 months.
• Patients with concurrent malignancy or ongoing anti-tumor therapy.
• Patients with history of being allergic to the trial medicine.
• Pregnancy, breastfeeding or potential pregnancy.
• Within three months or currently participating in another investigational study.
• Any other condition that in the opinion of the investigator should preclude study participation.

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

yongjun wang

OTHER_GOV

Sponsor Role: lead

Responsible Party

yongjun wang

Vice president of Beijing Tiantan Hospital

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Yongjun Wang, professor

Role: STUDY_DIRECTOR

Beijing Tiantan Hospital

Locations

Beijing TianTan Hospital,Capital Medical University

Beijing, , China

Countries

China

References

Dong Y, Jiang K, Li Z, Zhou Y, Ju B, Min L, He Q, Fan P, Hu W, Qu H, Wu H, Pan C, Cao Y, Lou X, Zhang G, Zhang J, Hu F, Dong Q; TISS Trial Investigators. Tongxinluo and Functional Outcomes Among Patients With Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Netw Open. 2024 Sep 3;7(9):e2433463. doi: 10.1001/jamanetworkopen.2024.33463.

Reference Type: DERIVED

PMID: 39325453 (View on PubMed)

Other Identifiers

yl-yxb09-lcsyfa-201301

Identifier Type: -

Identifier Source: org_study_id